Q1 2024 Personalis Inc Earnings Call Transcript
Key Points
- Personalis Inc (PSNL) achieved a revenue of $19.5 million in Q1 2024, surpassing the upper end of their guidance.
- Biopharma business grew by 55% compared to Q1 2023, driven by strong demand for core immunoassay platform and MRD product mix.
- Personalis Inc (PSNL) has increased its full-year revenue guidance to $76 million to $78 million, up from $73 million to $75 million.
- The company has successfully launched its ultrasensitive MRD test, NeXT Personal, with significant early adoption and positive feedback from physicians.
- Personalis Inc (PSNL) has established strong partnerships, including a key collaboration with Tempus to commercialize NeXT Personal, potentially worth $30 million.
- Despite revenue growth, gross margin decreased to 20.1% in Q1 2024 from 25.1% in the same period last year.
- The company reported a net loss of $13 million for Q1 2024, although this was an improvement from a $28.7 million loss in the previous year.
- Operating expenses, while reduced from the previous year, remain high at $24.4 million for Q1 2024.
- The company is engaged in ongoing litigation with Foresight Diagnostics to protect its intellectual property, indicating potential legal risks.
- Personalis Inc (PSNL) is cautious about expanding its early access program for NeXT Personal due to the current lack of reimbursement, which could limit short-term growth.
Good day and welcome to the Personalis First Quarter 2024 earnings conference call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Mr. Aaron Tachibana. Please go ahead.
Thank you, operator. Welcome to Personalis First Quarter 2024 earnings call. Joining today's call are Chris Hall, Chief Executive Officer and President and I am and then touch upon our Chief Financial and Chief Operating Officer, and Rich Chan, Chief Medical Officer and EVP of R&D.
All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the U.S. securities laws. For example, in statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
